Lisata Therapeutics (LSTA) News Today $2.54 -0.02 (-0.82%) Closing price 02/21/2025 03:50 PM EasternExtended Trading$2.50 -0.04 (-1.73%) As of 02/21/2025 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Lisata Therapeutics (LSTA) Expected to Announce Quarterly Earnings on ThursdayFebruary 22 at 1:57 AM | americanbankingnews.comLisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025February 20 at 8:00 AM | globenewswire.comLisata Therapeutics to Present at the 2025 BIO CEO & Investor ConferenceFebruary 5, 2025 | markets.businessinsider.comLisata Therapeutics CEO discusses recent pancreatic cancer trial milestones – ICYMIJanuary 25, 2025 | proactiveinvestors.comLisata Therapeutics CEO discusses recent pancreatic cancer trial milestones – ICYMIJanuary 25, 2025 | proactiveinvestors.comLisata Therapeutics reports preliminary Cohort A data from Phase 2 ASCEND trialJanuary 23, 2025 | markets.businessinsider.comLisata reports positive early trial results for pancreatic cancer drugJanuary 23, 2025 | msn.comLisata Therapeutics and WARPNINE unveil positive preliminary results from pancreatic cancer trialJanuary 23, 2025 | proactiveinvestors.comLisata Therapeutics Reports Trial Results for Pancreatic Cancer TreatmentJanuary 22, 2025 | yahoo.comLisata Therapeutics Shares Tumble After Pancreatic Cancer Treatment ResultsJanuary 22, 2025 | marketwatch.comLisata falls after mid-stage data for anticancer agentJanuary 22, 2025 | msn.comLisata Therapeutics unveils encouraging preliminary data from Phase 2 pancreatic cancer trialJanuary 22, 2025 | proactiveinvestors.comFirst Berlin sets Lisata stock Buy rating on innovative therapiesJanuary 21, 2025 | msn.comLisata Therapeutics to Present at the 2025 Sequire Investor SummitJanuary 15, 2025 | globenewswire.comLisata Therapeutics complete enrollment in CENDIFOX trialDecember 11, 2024 | markets.businessinsider.comLisata Therapeutics Completes Enrollment for Cancer Therapy TrialDecember 11, 2024 | finance.yahoo.comLisata Therapeutics advances certepetide with trial enrollment milestone and new diagnostic partnershipDecember 11, 2024 | proactiveinvestors.comLisata Therapeutics completes patient enrollment for CENDIFOX trialDecember 10, 2024 | proactiveinvestors.comLisata Therapeutics Announces Completion of Enrollment in the CENDIFOX TrialDecember 10, 2024 | globenewswire.comLisata and Kuva Labs partner for MR imaging agents to detect cancerDecember 6, 2024 | msn.comLisata Therapeutics, Kuva Labs enter license agreementDecember 4, 2024 | markets.businessinsider.comLisata Therapeutics and Kuva Labs to collaborate on cancer imaging solutionDecember 3, 2024 | proactiveinvestors.comLisata Therapeutics Wins 2024 BioTech Breakthrough Award for 'Specialized BioTherapeutics Company of the Year'November 21, 2024 | stockhouse.comLisata Therapeutics: Strong Financials and Diverse Clinical Progress Bolster Buy RatingNovember 21, 2024 | markets.businessinsider.comLisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’November 19, 2024 | markets.businessinsider.comLisata Therapeutics named ‘Specialized BioTherapeutics Company of the Year' at 2024 BioTech Breakthrough AwardsNovember 19, 2024 | proactiveinvestors.comLisata Therapeutics named ‘Specialized BioTherapeutics Company of the Year' at 2024 BioTech Breakthrough AwardsNovember 19, 2024 | proactiveinvestors.comLisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year'November 19, 2024 | globenewswire.comLisata Therapeutics CEO discusses pancreatic cancer trial progress and new collaborations - ICYMINovember 16, 2024 | proactiveinvestors.comLisata Therapeutics Reports Q3 2024 Financial ResultsNovember 13, 2024 | markets.businessinsider.comLisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ...November 13, 2024 | finance.yahoo.comLisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comEarnings Outlook For Lisata TherapeuticsNovember 12, 2024 | benzinga.comLisata Therapeutics advances clinical trials in Q3 ahead of 'data-rich' 2025November 12, 2024 | proactiveinvestors.comLisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | globenewswire.comLisata Therapeutics, Valo Therapeutics enter preclinical research collaborationNovember 7, 2024 | markets.businessinsider.comLisata Therapeutics and Valo Therapeutics partner in preclinical study on cancer immunotherapyNovember 6, 2024 | proactiveinvestors.comLisata Therapeutics and Valo Therapeutics Announce Preclinical Research CollaborationNovember 6, 2024 | globenewswire.comLisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024November 6, 2024 | globenewswire.comLisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapy - ICYMINovember 2, 2024 | proactiveinvestors.comLisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor EventsOctober 31, 2024 | globenewswire.comLisata Therapeutics entered research agreement with University of CincinnatiOctober 28, 2024 | markets.businessinsider.comLisata Therapeutics strikes research partnership to investigate new treatment for endometriosisOctober 28, 2024 | proactiveinvestors.comLisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of EndometriosisOctober 28, 2024 | globenewswire.comRAPT Therapeutics (NASDAQ:RAPT) Stock Quotes, Forecast and News SummaryOctober 3, 2024 | benzinga.comLisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor EventsOctober 3, 2024 | finance.yahoo.comAdaptive Biotechnologies (NASDAQ:ADPT) Stock Quotes, Forecast and News SummarySeptember 27, 2024 | benzinga.comStrong Buy Rating for Lisata Therapeutics Backed by Promising Certepetide Clinical PerformanceSeptember 19, 2024 | markets.businessinsider.comLisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER TrialSeptember 17, 2024 | finance.yahoo.comLisata Therapeutics begins treating second cohort of patients in bile duct cancer trialSeptember 17, 2024 | proactiveinvestors.com Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address LSTA Media Mentions By Week LSTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LSTA News Sentiment▼0.000.60▲Average Medical News Sentiment LSTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LSTA Articles This Week▼22▲LSTA Articles Average Week Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Oramed Pharmaceuticals News Today Protara Therapeutics News Today X4 Pharmaceuticals News Today Immunic News Today Mersana Therapeutics News Today DBV Technologies News Today Cellectis News Today Citius Oncology News Today Scilex News Today Cue Biopharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LSTA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
